Advertisement

Schizophrenie pp 138-148 | Cite as

D1- und kombinierte D1-/D2-Rezeptorblockade bei Schizophrenie

  • J. Gerlach
Conference paper

Zusammenfassung

Der antipsychotische Effekt konventioneller Neuroleptika wird ihren D2-rezeptorblockierenden Eigenschaften zugeschrieben. Verschiedene Forschungsansätze haben eine positive Korrelation zwischen dem Grad der D2-Rezeptorblockade und dem antipsychotischen Effekt nachgewiesen (Übersichten bei Seeman 1992; Farde et al. 1992). Die Blockade der D2-Rezeptoren ist jedoch bei weitem nicht ideal:
  • Die therapeutische Wirkung ist unzureichend. Etwa 20% der Schizophreniepatienten zeigen keine oder nur eine minimale Besserung, während bei den übrigen, d. h. der Mehrheit schizophrener Patienten, eine unterschiedlich starke Reduktion der Symptome zu beobachten ist. Nur bei wenigen Patienten kommt es zu einer vollständigen und anhaltenden Remission. In den meisten Fällen bleiben einige Symptome bestehen, wenn auch in abgeschwächter Form.

  • Alle Antipsychotika haben Nebenwirkungen, die von einer geringfügigen, oft unbemerkten Verschlechterung der psychischen Funktionen (wie Anhedonie und verminderter Lebensfreude) bis hin zu potentiell irreversiblen Spätdyskinesien und dem tödlichen malignen Neuroleptikasyndrom reichen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (1992) NNC 0112 and NNC 0756, new selective and highly potent D1 antagonists. Eur J Pharmacol 219: 45–52PubMedCrossRefGoogle Scholar
  2. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psycho-pharmacology 99: 47–53Google Scholar
  3. Casey DE (1992) Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology 107: 18–22PubMedCrossRefGoogle Scholar
  4. Christensen AV (1990) Long-term effects of dopamine D1 and D2 antagonists in vervet monkeys. Behavioural Neurol 3: 49–60Google Scholar
  5. Coffin VL, Latranyi MB, Chipkin RE (1989) Acute extrapyramidal syndromes in cebus monkeys: development mediated by dopamine D2 but not D1 receptors. J Pharmacol Exp Ther 249: 769–774PubMedGoogle Scholar
  6. Coffin VL, Barnett A, McHugh DT (1991) Reversal of extrapyramidal side effects with SCH 39166, a dopamine D1 receptor antagonist. Abstr ACNP (30th Annual Meeting, Pourto Rico, Dec 1991 )Google Scholar
  7. Dittman RW (1993) Olanzepine: pharmacological characteristics and first clinical experiences. Pharmacopsychiatry 26: 147Google Scholar
  8. Fabre LF (1993) A multicenter, open pilot trial of ICI 204.636 in hospitalized patients with acute psychotic symptomatology. Schizophr Res 9: 237CrossRefGoogle Scholar
  9. Farde L (1992) Selective D1 or D2 dopamine receptor blockade induces akathisia in humans a PET study with [11C] SCH 23390 and [11C]raclopride. Psychopharmacology 107: 23–29PubMedCrossRefGoogle Scholar
  10. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine — relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538–544PubMedGoogle Scholar
  11. Fitton A, Heel RC (1990) Clozapine. A review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 40: 722–747PubMedCrossRefGoogle Scholar
  12. Gerlach J (1991) New antipsychotics: Classification, efficacy and adverse effects. Schizophr Bull 17: 289–309PubMedGoogle Scholar
  13. Gerlach J, Hansen L (1992) Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychatr 160 [Suppl]: 34–37Google Scholar
  14. Gerlach J, Hansen L (1993) Effect of chronic treatment with NNC 756, a new D1 antagonist, or raclopride, a D2 receptor antagonist, in drug-naive cebus monkeys. J Psychopharmacol 7: 355–364CrossRefGoogle Scholar
  15. Glenthøj B, Bolwig TG, Hemmingsen R (1991) Continuous versus discontinuous neuroleptic treatment in an animal model of tardive dyskinesia. In: Racacini IG et al. (eds) Biological psychiatry, vol 1. Elsevier, Amsterdam, pp 602–604Google Scholar
  16. Hamilton M, Card IR, Wallis GG, Mahmoud MR (1979) A comparative trial of tge decanoates of flupenthixol and fluphenazine. Psychopharmacology 64: 225–229PubMedCrossRefGoogle Scholar
  17. Heikkilä L, Laitineri J, Vartianen H (1981) Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients — a double-blind clinical multicentre investigation. Acta Psychiatr Scand 64 [Suppl] 2941: 30–38Google Scholar
  18. Heikkllä L, Eliander H, Vartiainen H, Turunen M, Pedersen V (1992) Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multicentre study. Curr Med Res Opin 12: 594–603CrossRefGoogle Scholar
  19. Johnson DAW, Malik NA (1975) A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatr Scand 51: 257–267PubMedGoogle Scholar
  20. Kane J, Honigfeld G, Singer J, Meltzer HY (Clozaril Collaborative Study Group) (1988) Clozapine for the treatment-resistent schizophrenic. Arch Gen Psychiatry 45: 789–796PubMedGoogle Scholar
  21. Liebermann J, Johns C, Cooper T, Pollack S, Kane J (1989) Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 99: 54–59CrossRefGoogle Scholar
  22. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvaneri E (1991) Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacology 1: 541–548CrossRefGoogle Scholar
  23. Lublin H, Gerlach J, MOrkebjerg F (The NNC Study Group) (1994a) The potential antipsychotic effect of selective D1 antagonists evaluated in monkeys and in an open clinical study. Psychopharmacology (in press)Google Scholar
  24. Lublin H, Gerlach J, Mtrkeberg F (1994b) Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists. Psychopharmacology (in press)Google Scholar
  25. Lundin L, Dencker SJ, Malm U (1990) Community-based rehabilitation of schizophrenia. Nord Psykiatr Tidskr 44: 81–87CrossRefGoogle Scholar
  26. Malick J (1990) ICI 204.636, a novel atypical antipsychotic: early indication for safety and efficacy in man. Abstract book, vol 11, p 223 (17th Congress of Collegium Internationale Neuropsychopharmacologicum, Kyoto)Google Scholar
  27. Markstein R, Amstutz R, Jaton A, Urwyler S, Ruedeberg C, Imperato A (1992) SDZ DOD-647, a new clozapine-like atypical neuroleptic drug. Schizophr Res 244Google Scholar
  28. Meltzer H (1992) Dimensions of outcome with clozapine. Br J Psychiatry 160 [Suppl] 71: 46–53Google Scholar
  29. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olan-zepine, a novel „atypical“ antipsychotic agent. J Pharmacol Exp Ther 262: 545–551PubMedGoogle Scholar
  30. Peacock L (1994) Atypical versus typical antipsychotics: Effects and side effects in a mon- key model. In: Rey O (ed) CINP-abstract book (in press)Google Scholar
  31. Pinto R, Bannerjee A, Ghosh N (1979) A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatr Scand 60: 313–322PubMedCrossRefGoogle Scholar
  32. Seeman P (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7: 261–284PubMedGoogle Scholar
  33. Simpson GM, Lee JH, Shrivastava RK (1978). Clozapine in tardive dyskinesia. Psycho-pharmacology 56: 75–80Google Scholar
  34. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151PubMedCrossRefGoogle Scholar
  35. Szegedi A, Wiesner J, Hillert A, Hammes E, Wetzel H, Benkert O (1993) ICI 204636, a putative „atypical“ antipsychotic, in the treatment of schizophrenia with positive symptomatology: an open clinical trial. Pharmacopsychiatry 26: 197Google Scholar
  36. Thomas P, Lalaux, Rocielet P, Destée A, Goudemand M (1993) Lasting dystonia with clozapine. Abstracts, p 191 (9th World Congress of Psychiatry, June 6–12 1993)Google Scholar
  37. Waddington JL (1991) Pre-and postsynaptic D1 to D5 dopamine receptor mechanisms in relation to antipsychotic activity. In: Barnes T (ed) Antipsychotic drugs and their side effects. Academic Press/Harcourt Brace, London Boston Tokyo, pp 66–85Google Scholar
  38. Wistedt B, Koskinen T, Thelander S, Nerdrum T. Pedersen V, Molbjerg C (1991) Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand 84: 14–21PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • J. Gerlach

There are no affiliations available

Personalised recommendations